Pregled bibliografske jedinice broj: 1106859
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? // American journal of physiology. Heart and circulatory physiology, 319 (2020), 4; H793-H796 doi:10.1152/ajpheart.00506.2020 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1106859 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse
outcome?
(COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?)
Autori
Jakovac, Hrvoje
Izvornik
American journal of physiology. Heart and circulatory physiology (0363-6135) 319
(2020), 4;
H793-H796
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
COVID-19 ; HSP60 ; hypertension ; mizoribine ; SARS-CoV-2 ; severity
Sažetak
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? Am J Physiol Heart Circ Physiol 319: H793–H796, 2020. First published September 4, 2020 ; doi:10.1152/ajpheart.00506.2020.—The 60-kDa heat shock protein (HSP60) is a chaperone essential for mitochondrial proteostasis ensuring thus sufficient aerobic energy production. In pathological conditions, HSP60 can be translocated from the mitochondria and excreted from the cell. In turn, the extracellular HSP60 has a strong ability to trigger and enhance inflammatory response with marked proinflammatory cytokine induction, which is mainly mediated by Toll-like receptor binding. Previous studies have found increased circulating levels of HSP60 in hypertensive patients, as well as enhanced HSP60 expression and membrane translocation in the hypertrophic myocardium. These observations are of particular interest, since they could provide a possible pathophysiological explanation of the severe course and worse outcome of severe acute respiratory syndrome coronavirus 2 infection in hypertensive patients, repeatedly reported during the recent coronavirus disease 2019 (COVID-19) pandemic and related to hyperinflammatory response and cytokine storm development during the third phase of the disease. In this regard, pharmacological inhibition of HSP60 could attract attention to potentially ameliorate inappropriate inflammatory reaction in severe COVID-19 patients. Among HSP60 antagonizing drugs, mizoribine is the most intriguing, since it is clinically approved and exerts antiviral activity. However, this topic requires to be further scrutinized.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE